Sponsor pipeline

QuantumLeap Healthcare Collaborative clinical trial pipeline

Get alerts when QuantumLeap Healthcare Collaborative's trials change

4 active trials 3 recruiting 5 disease areas 8 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days

2026-09-03
Primary completion pushed: 2028-12-30 → 2030-12-30
Primary endpoint(s) modified
Phase changed: Phase 1 → Phase 1/2
Enrollment increased: 124 → 280 participants
Interventions modified
Trial sites expanded: 7 → 10 locations
Completion pushed: 2029-12-30 → 2031-12-30
Trial arms changed: 2 → 3
NCT05868226 PRE-ISPY Phase I/II Oncology Platform Program · Phase 1/2

Active trials by phase

Phase 1/2
1
Phase 2
3

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2
NCT06075953 DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active… Ductal Carcinoma in Situ Recruiting 2026-07-21
NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Breast Neoplasms Recruiting 2026-05-06
NCT04488081 I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients COVID-19 Active, Not Recruiting 2026-03-16
Phase 1/2
NCT05868226 PRE-ISPY Phase I/II Oncology Platform Program HER2-positive Breast Cancer Recruiting 2026-09-02

Disease areas by active trials

Breast Cancer (2) · HER2-Positive Breast Cancer (2) · Triple-Negative Breast Cancer (2) · Colorectal Cancer (1) · Sarcoma (1)

Get alerts when QuantumLeap Healthcare Collaborative's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free